WARRANT AGENT AGREEMENTWarrant Agent Agreement • October 11th, 2022 • Bone Biologics Corp • Orthopedic, prosthetic & surgical appliances & supplies • New York
This Warrant Agent Agreement (this “Warrant Agreement”), dated as of October 7, 2022 (the “Issuance Date”) between Bone Biologics Corp., a company incorporated under the laws of the State of Delaware (the “Company”), and Equiniti Trust Company, a limited trust company organized under the laws of the State of New York (the “Warrant Agent”).
BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT 3,777,778 Units Consisting of 3,777,778 Shares of Common Stock, And 3,777,778 Series A Warrants to Purchase 3,777,778 Shares of Common Stock And 3,777,778 Series B Warrants to Purchase 3,777,778 Shares...Underwriting Agreement • October 11th, 2022 • Bone Biologics Corp • Orthopedic, prosthetic & surgical appliances & supplies • New York
BONE BIOLOGICS CORPORATION, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”), an aggregate of 3,777,778 Units (the “Firm Units”), each Firm Unit consisting of: (i) one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”); (ii) one Series A warrant to purchase one share of Common Stock (the “Series A Warrants” and each a “Series A Warrant”); (iii) one Series B warrant to purchase one share of Common Stock (the “Series B Warrants” and each a “Series B Warrant”); and (iv) one Series C warrant to purchase one share of Common Stock (the “Series C Warrants” and each a “Series C Warrant” and together with Series A Warrants and Series B Warrants, the Purchase Warrants). The 3,777,778 shares of Common Stock referred
